WuXi com­pa­nies con­sid­er sale of units im­pact­ed by Biose­cure; J&J, Bay­er trim staff; Ron Re­naud’s lat­est biotech; and more 

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER